RAB4B蛋白研究进展

 利用细胞工程生产的药品主要包括疫苗、基因工程药物、基因治疗药物、抗体药物以及动物疫苗等生物制品，随着生物技术的发展，利用细胞工程表达、分泌生产的生物制品越来越多。在我国，疫苗（包括人和动物疫苗）的生产主要采用贴壁细胞转瓶培养的生产方式，如培养VERO细胞（非洲绿猴肾细胞）用于乙型脑炎、出血热、甲型肝炎、狂犬病疫苗的生产，培养地鼠肾细胞用于乙型脑炎、狂犬病疫苗的生产，培养BHK21细胞（仓鼠肾细胞）用于口蹄疫疫苗的生产，培养CHO细胞（中国仓鼠卵巢细胞）用于重组乙型肝炎疫苗的生产，培养二倍体细胞（人胚肺细胞）用于甲型肝炎、水痘疫苗的生产等等。而生产抗体、蛋白药物则需要采用生物反应器无血清全悬浮培养CHO、NSO（骨髓瘤细胞）等细胞进行蛋白表达。因此，不断研发细胞大规模培养技术，是提高我国细胞工程制药技术水平的重要基础。结合目前国际生物技术发展状况和我国生产实际现状，笔者认为我国的细胞工程疫苗生产应该重视以下两个方面的问题。...     

开设住院医师论坛的实践与效果

目的对我院6年来开设住院医师论坛（以下简称论坛）进行总结。方法论坛每2周举办1次,参加对象为全体住院医师,每人每年有一次主题发言。主讲人必须制作英文课件和用英文报告自己所负责的一些疑难或少见病例,每次论坛有指导教师现场为主讲人评分。结果论坛促进了住院医师的专业知识学习,提高了住院医师的临床思维、文献检索、英文应用和语言表达等综合能力;论坛是对住院医师培训内容的补充与完善;论坛促进了教学互动、活跃了学术氛围,不仅提高了住院医师的综合能力,对指导教师也是挑战;论坛继承与提高了医院的优良文化传统,为“临床型”医院向“学院型”医院转变打下了良好的基础。     

谈“博士论坛”及“百家讲坛”在军医院校博士生创新培养中的应用

针对军医院校特点和博士生教育培养工作过程的实际,在坚持以人才培养为中心的基础上,配合常规教学,介绍了以“博士论坛”、“百家讲坛”为载体的军医院校博士生创新培养的一些做法及效果.     

Controversies in sepsis clinical trials: proceedings of a meeting of the International Sepsis Forum, Lausanne, Switzerland, September 29, 2001

Despite some recent success with clinical trials studying innovative therapies in sepsis, the field remains predominantly one of failure despite compounds with significant preclinical activity. Preclinical animal experimentation remains an important component of drug development, and a portfolio approach is recommended. Failure in animals is more likely to predict failure in humans; however, success in animals often does not predict success in humans. Because the signal with innovative therapy of sepsis is likely to be low, an oncology model clinical trial approach, in which studies start with a high-risk homogeneous population and look for a large treatment effect with smaller numbers of patients, is likely to be more relevant than the commonly used cardiology model, in which studies search for a small treatment effect using large, heterogeneous, low-risk populations. With certain rules in place, improvement in organ function may be a worthwhile alternative to mortality as a clinical end point. Once a therapy is approved, adopting less stringent but still appropriate criteria for the use of that therapy in clinical practice may be appropriate.     

聚焦肝衰 共谋发展——第二届京津冀肝衰竭国际论坛、肝衰竭临床诊疗与前沿进展学习班会议报道

正2017年9月15日—9月16日,第二届京津冀肝衰竭国际论坛、肝衰竭临床诊疗及前沿进展学习班在北京隆重开班。本次大会的主题为传承发展、合作创新。会议围绕以下几个专题进行了报告和交流:(1)肝衰竭患者的分级管理探索;(2)肝衰竭基础研究进展;(3)肝衰竭的临床治疗;(4)肝衰竭相关并发症的诊断和治疗;(5)肝移植面临的挑战。     

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib

The multitargeted kinase inhibitors (MKIs) sorafenib and sunitinib have shown benefit in patients with renal cell carcinoma, hepatocellular carcinoma (sorafenib), and gastrointestinal stromal tumor (sunitinib). Their efficacy in other malignancies is currently being investigated because of their broad range of activity. The effectiveness of these drugs is somewhat diminished by the development of a variety of toxicities, most notably hand-foot skin reaction (HFSR). Although HFSR does not appear to directly affect survival, it can impact quality of life and lead to MKI dose modification or interruption, potentially limiting the antitumor effect. Currently, no standard guidelines exist for the prevention and management of MKI-associated HFSR. To address this issue, an international, interdisciplinary panel of experts gathered in January 2008 to discuss and evaluate the best-practice management of these reactions. Based on these proceedings, recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy.